Key result
Resveratrol-loaded nanoparticles outperform conventional resveratrol in preventing cardiac injury in rats with induced MI.
Why the study?
The study evaluated the effects of pretreatment with resveratrol-loaded PLGA nanoparticles compared to conventional resveratrol on isoproterenol-induced myocardial infarction in rats.
Does pretreatment with RSV PLGA NPs improve cardioprotection against isoproterenol-induced myocardial infarction in rats compared to conventional resveratrol?
RCT (n=60)
randomly divided
Does pretreatment with RSV PLGA NPs improve cardioprotection against isoproterenol-induced myocardial infarction in rats compared to conventional resveratrol?
Improving the bioactivity of resveratrol using PLGA nanoparticles enhances its cardioprotective, antioxidant, and anti-inflammatory effects against isoproterenol-induced myocardial infarction in a rat model.
Does not support clinical use of resveratrol nanoparticles; extends preclinical evidence but leaves translation to humans open.
Our study is aimed at evaluating the effects of pretreatment with Poly(lactic-co-glycolic) acid nanoparticle loaded with resveratrol (RSV PLGA NPs) compared to conventional resveratrol (RSV) on isoproterenol (ISO) induced myocardial infarction (MI) in rats. Sixty rats were randomly divided into six groups of 10 rats each. RSV and RSV PLGA NPs were given by gavage in two different doses (50 mg/kg body weight [BW] and 100 mg/kg BW) for 3 weeks. RSV and RSV PLGA NPs were given for 2 weeks starting 1 week before ISO administration. The blood samples were taken 24 hr after the last dose of ISO. The antioxidant, anti-inflammatory, and cardioprotective effects were evaluated in all groups. Only 100 mg/kg dose of RSV and both doses of RSV PLGA NPs offered a cardioprotective effect by preventing cardiac troponin T (cTnT) levels, lactate dehydrogenase (LDH), and aspartate aminotransferase (AST) activities leakage from cardiomyocytes, with the best result for RSV PLGA NPs. All the oxidative stress parameters were significantly improved after RSV PLGA NPs compared to RSV pretreatment. RSV PLGA NPs were more efficient than RSV in limiting the increase in inflammatory cytokine expressions such as tumor necrosis factor-alpha (TNF-α), interleukin 1 beta (IL-1β), and NF-kappaB (NF-kB) expression. In addition, RSV PLGA NPs significantly upregulated eNOS expression and downregulated iNOS expression. RSV PLGA NPs better prevented myocardial necrosis and reduced interstitial edema and neutrophil infiltration than RSV, on histopathological examination. Therefore, improving the bioactivity of RSV by nanotechnology may help limit cardiac injury after myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2020) conducted an RCT in isoproterenol-induced myocardial infarction (n=60). Poly(lactic-co-glycolic) acid nanoparticle loaded with resveratrol (RSV PLGA NPs) vs. conventional resveratrol (RSV) was evaluated on cardioprotective effects (cTnT, LDH, AST, oxidative stress, and inflammatory cytokines). Pretreatment with resveratrol-loaded PLGA nanoparticles was more effective than conventional resveratrol in preventing cardiac injury, oxidative stress, and inflammation in rats with induced MI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: